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PRS1
DIRECT AND INDIRECT COSTS OF ASTHMA TO 
AN EMPLOYER
Birnbaum HG1, Greenberg PE1, Wanke LA2, Atkins K2
1Analysis Group/Economics, Cambridge, MA, USA; 2Immunex 
Corporation, Seattle, WA, USA
OBJECTIVES: Asthma is a debilitating condition that
can lead to significant adverse economic consequences.
This study investigated the extent that asthma imposes
significant financial burdens on the employer. METH-
ODS: The data source is an exceptionally rich adminis-
trative claims database for a national Fortune 100 manu-
facturer. It includes medical, pharmaceutical, and disability
claims for 1998 for employees, spouses, dependents, and
retirees (n  100,000). The research sample consisted of
individual patients with one or more medical or disability
claims for asthma. Resource utilization in the asthma
sample was contrasted with that of a 10% random sam-
ple of the employer’s overall beneficiary population. RE-
SULTS: The analysis included both direct (medical and
pharmaceutical) and indirect (disability and sporadic ab-
senteeism) costs. The average annual costs were: for the
entire employer population $2259; for asthma patients
$3962; for asthma patients eligible for disability $6983;
and for disability claimants with asthma $13,796. Total
costs for asthma patients were 1.8 times those for the
typical beneficiary. Medical and pharmaceutical treat-
ment accounted for 78% of total costs for asthma pa-
tients, while the remaining 22% was for wage replace-
ments for workdays lost for disability and sporadic
absenteeism. For employees, the average prevalence for
disability was 2.0 times greater among asthma patients
than among employees overall. CONCLUSIONS: Asthma
imposes a significant financial burden on the employer.
Resource utilization by asthma patients is substantial,
not only for the direct treatment of asthma, but also for
the treatment of co-morbid medical conditions of asthma
patients. The study also showed that asthma imposes
substantial indirect costs on employers, primarily from
the unusually high rates of disability associated with this
illness.
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IMPACT OF A TARGETED ASTHMA 
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TREATMENT COSTS
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Appropriate drug therapy, according to the guidelines by
the National Heart, Lung, and Blood Institute (NHLBI),
can improve patient’s quality of life and reduce total
treatment costs. However, few studies have assessed
changes in asthma treatment costs following adherence
to these guidelines. OBJECTIVES: The purpose of this
study was to evaluate the impact of a targeted asthma in-
tervention on treatment costs from the third party’s per-
spective. METHODS: This longitudinal population-based
study (1/1997–12/1998) compared asthma treatment
costs for 9 months before and 9 months after interven-
tion in intervention and control groups. A 3-month
washout period was applied to minimize any possible
carryover effects into the post-intervention phase. All
costs were deflated to 1997 dollars. Costs were also com-
pared based on patient’s drug therapy. A paired t-test or
a Wilcoxon signed rank test were used to compare costs
before and after the intervention, depending on the char-
acteristics of the sample. RESULTS: The intervention
group (IG) consisted of 1933 patients and the control
group (CG) consisted of 2447 patients. Following the in-
tervention, the average asthma medication cost per pa-
tient increased from $195 to $198 (P  0.357), but med-
ical costs decreased from $350 to $260 (P  0.05) in the
IG. The average number of asthma prescriptions per pa-
tient decreased from 6.69 to 6.30 in the IG (P  0.01)
while the number in the CG increased from 2.15 to 2.54
(P  0.01). The cost of asthma medications for patients
who use excess quick acting inhaled 2 agonist before in-
tervention but received proper drug therapy according to
the guidelines after intervention, increased from $91 to
$142 (P  0.01) however medical costs decreased from
$321 to $261 (P  0.05). CONCLUSIONS: A targeted
asthma intervention, according to the NHLBI guidelines,
resulted in a significant decrease in total asthma treat-
ment costs, with an increment in asthma medication
costs, but a decrease in asthma medical costs.
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BACKGROUND: The excessive use of -agonist medica-
tions by asthmatics has been identified as a significant
risk factor for increased morbidity and mortality. The
objective of this analysis is to evaluate -agonist users in
BC to determine if -agonist utilization is decreasing, as
recommended by current asthma management guidelines.
METHODS: Asthma medication prescription records
were obtained from BC Pharmacare for all patients in BC
covered by Pharmacare who received at least one pre-
scription for a -agonist medication in 1996, 1997, and
1998. Annual -agonist use was standardized to salbutamol
100 mcg, 200 doses/canister. Cross-sectional and longitu-
dinal analyses were undertaken to identify potential
144 Abstracts
trends in the excessive use of -agonist medications. RE-
SULTS: Data from 13,481 patients covered by Pharma-
care PlanC (social assistance–first dollar coverage) or PlanE
(individuals or families exceeding deductible) were ana-
lyzed. In 1996, 1898 patients (14.1%) were high users of
-agonists (12 canisters/yr) compared to 1686 (12.5%)
in 1998 (P  0.001). 1119 patients (59%) who were high
users in 1996 remained high users in 1998, 38.7% of which
continued to use 20 canisters/yr. Of those patients us-
ing  12 canisters in 1996, only 4.9% increased their use
to 12 canisters/yr in 1998. 116 patients prescribed  4
canisters in 1996 substantially increased their use to 12
canisters in 1998. Age was positively associated with the
number of canisters prescribed (r  0.21; P  0.001);
only 4% of patients 19 years used 12 canisters in
1998 compared to 16% of patients  19 yrs. Age was
also associated with increasing use over the 3 years (P 
0.001). CONCLUSIONS: This analysis suggests a trend
in asthma management towards decreasing -agonist
use. However, 10% of -agonist users in this popula-
tion continued to use excessive or increasing amounts of
-agonists despite current treatment guidelines, putting
them at greater risk for -agonist related morbidity and
mortality, and increased health care utilization.
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IDENTIFYING PREDICTORS OF THE ASTHMA-
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The Asthma-specific quality of life questionnaire (AQLQ-
NAA) is a 19-item questionnaire and has emphasis on re-
strictions in social, community and cultural activities.
Three domains of the AQLQ-NAA, community and so-
cial restrictions (CSR, 10 items), psychological and im-
pact (PIM, 4 items) and symptoms (SYM, 5 items) have
been identified using principal component analysis. OB-
JECTIVES: The purpose of this study was to identify sig-
nificant predictors of the AQLQ-NAA and each of its do-
mains. METHODS: The AQLQ-NAA was administered
to a sample of 51 adult volunteers with a diagnosis of
asthma at the Albuquerque Indian Hospital and three af-
filiated clinics. Four forward stepwise regression models
were analyzed using total AQLQ-NAA scores and each
domain score separately as the criterion variable. Six pre-
dictors (emergency care visits in the past 6 months, hos-
pitalizations in the past six months, physician visits in the
past six months, corticosteroids used in the past six
months, asthma medications used in the past six months,
and patient gender) were used in the regression models.
RESULTS: Physician visits, hospitalizations and gender
were significant predictors of total AQLQ-NAA scores
(F  10.493, P  0.05, Adjusted R2  0.388) and the
CSR domain scores (F  10.537, P  0.05, Adjusted
R2  0.389). Physician visits and hospitalizations were
significant predictors of the PIM domain scores (F 
13.368, P  0.05, Adjusted R2  0.355). Number of
asthma medications and gender were significant predic-
tors of the SYM domain scores (F  7.107, P  0.05,
Adjusted R2  0.213). CONCLUSIONS: Based on the
predictors for each of the three domains, inherent differ-
ences between the domains were observed. This study
helps further establish evidence of construct validity of
the AQLQ-NAA and its domains.
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1Advance Paradigm, Hunt Valley, MD, USA, 2Glaxo Wellcome, 
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OBJECTIVES: The purpose of this study is to evaluate
differences in asthma-related health care resource utiliza-
tion between six months preceding and following the ini-
tiation of fluticasone propionate. METHODS: Adult
asthmatics were identified through administrative medical
and pharmacy claims from an IPA model Health Mainte-
nance Organization. The study population was defined
as any identified asthmatic with continuous enrollment
who had a prescription for fluticasone propionate. Asthma-
related resource utilization was evaluated for differences
in services based on the introduction of fluticasone propi-
onate. RESULTS: A total of 199 asthmatic members
were identified with an average age of 44.7 (12.7) years
old. The majority of patients (60%) were female. There
was an inverse relationship of pharmacy costs to medical
costs from the pre- to post-fluticasone propionate period.
Pharmacy costs increased 61%, while medical costs de-
creased 71 percent. Paired-sample t-tests showed a signif-
icant decrease in the number of hospitalizations, emer-
gency room visits, and diagnostic procedures. Although
pharmacy utilization increased, it resulted in an improved
inhaled corticosteroid to beta-2 agonist ratio of 0.51 to
1.41. The net asthma-related costs declined 35%, repre-
senting a reduction of $296 per asthma study member for
the six-month period. CONCLUSIONS: In summary, the
introduction of fluticasone propionate appeared to have
a substantial impact on resource utilization and cost. Re-
sults support current literature that the use of inhaled
corticosteroids reduces the number of asthma-related
emergency room visits and hospitalizations.
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